Geneos Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-200
Closed -$6K – 2598
2022
Q1
$6K Hold
200
– – ﹤0.01% 2261
2021
Q4
$8K Sell
200
-405,552
-100% -$17.4M ﹤0.01% 2253
2021
Q3
$18.5M Buy
405,752
+405,552
+202,776% +$20.5M 0.71% 27
2021
Q2
$9K Hold
200
– – ﹤0.01% 2222
2021
Q1
$8K Hold
200
– – ﹤0.01% 2456
2020
Q4
$8K Hold
200
– – ﹤0.01% 2292
2020
Q3
$6K Sell
200
-240,834
-100% -$8.54M ﹤0.01% 2104
2020
Q2
$8.54M Buy
241,034
+240,668
+65,756% +$7.68M 0.48% 41
2020
Q1
$7K Sell
366
-202,540
-100% -$5.64M ﹤0.01% 1925
2019
Q4
$6.35M Buy
202,906
+202,540
+55,339% +$5.4M 0.34% 72
2019
Q3
$7K Hold
366
– – ﹤0.01% 1994
2019
Q2
$9K Hold
366
– – ﹤0.01% 1928
2019
Q1
$10K Hold
366
– – ﹤0.01% 1830
2018
Q4
$7K Sell
366
-114,900
-100% -$3M ﹤0.01% 1868
2018
Q3
$4.01M Buy
115,266
+114,900
+31,393% +$3.76M 0.27% 107
2018
Q2
$10K Hold
366
– – ﹤0.01% 1709
2018
Q1
$10K Hold
366
– – ﹤0.01% 1632
2017
Q4
$10K Sell
366
-64,600
-99% -$1.82M ﹤0.01% 1623
2017
Q3
$1.99M Buy
64,966
+64,600
+17,650% +$1.84M 0.2% 124
2017
Q2
$9K Hold
366
– – ﹤0.01% 1561
2017
Q1
$8K Hold
366
– – ﹤0.01% 1545
2016
Q4
$7K Hold
366
– – ﹤0.01% 1527
2016
Q3
$8K Buy
366
+200
+120% +$4.75K ﹤0.01% 1429
2016
Q2
$3K Hold
166
– – ﹤0.01% 1604
2016
Q1
$3K Hold
166
– – ﹤0.01% 1589

Other funds holding BIB

Geneos Wealth Management's BIB Position: Q2 2022 in Review

Geneos Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2022, closing a stake of 200 shares — an estimated $6K sold.

Geneos Wealth Management first reported a position in BIB in Q1 2016 and held it in 25 quarters. The position peaked at $18.5M in Q3 2021. 24 funds tracked by Wall St. Rank hold BIB as of Q2 2022.

  • Geneos Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 200 ProShares Ultra NASDAQ Biotechnology shares in Q2 2022, an estimated $6K.
  • Geneos Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and held it in 25 quarters.
  • Geneos Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $18.5M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2022.

Based on Geneos Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.